Halofuginone (Standard)

CAT: 0804-HY-N1584R-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-N1584R-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Halofuginone (Standard) is the analytical standard of Halofuginone. This product is intended for research and analytical applications. Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM[1][2]. Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity[3][4]. Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects[5].
CAS Number
[55837-20-2]
Product Name Alternative
RU-19110 (Standard)
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Calcium Channel; DNA/RNA Synthesis; Parasite; Reference Standards; Sodium Channel; TGF-beta/Smad
Type
Reference compound
Related Pathways
Anti-infection; Cell Cycle/DNA Damage; Membrane Transporter/Ion Channel; Neuronal Signaling; Others; Stem Cell/Wnt; TGF-beta/Smad
Field of Research
Cancer; Infection; Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/halofuginone-standard.html
Purity
99.73
Smiles
O=C1N(CC(C[C@@H]2NCCC[C@H]2O)=O)C=NC3=C1C=C(Cl)C(Br)=C3
Molecular Formula
C16H17BrClN3O3
Molecular Weight
414.68
Precautions
H302, H315, H319, H335
References & Citations
[1]Tsuchida K, et al. Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation. Free Radic Biol Med. 2017 Feb;103:236-247.|[2]Keller TL, et al. Halofuginone and other Febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol. 2012 Feb 12;8 (3) :311-7.|[3]Cui Z, et al. Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone. Ann Rheum Dis. 2016 Sep;75 (9) :1714-21.|[4]Tracy L McGaha, et al. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol. 2002 Mar;118 (3) :461-70.|[5]Pritesh P Jain, et al. Halofuginone, a Promising Drug for Treatment of Pulmonary Hypertension. Br J Pharmacol. 2021 Mar 10.
Shipping Conditions
Room Temperature
Storage Conditions
4°C, sealed storage, away from light and moisture
Scientific Category
Reference Standards

Related Products

CatalogName
HY-N1584BRHalofuginone (hydrochloride) (Standard)
HY-N1584AR-01Halofuginone (hydrobromide) (Standard)
HY-N1584-01Halofuginone
HY-N1584A-01Halofuginone (hydrobromide)
HY-N1584C-01Halofuginone (lactate)
HY-N1584BHalofuginone (hydrochloride)
HY-156882Biotin-PEG3-amide-C2-CO-Halofuginone
HY-W783671RPerlolyrin (Standard)
HY-W380450R-01Viloxazine (Standard)
HY-W376701R-01Guanadrel (Standard)

Alternative Products

CatalogName
MBS340798-01Halofuginone
451693-01Halofuginone Lactate
278846-01Halofuginone hydrobromide
278847-01Halofuginone hydrochloride

Popular Products